Table 1.
Revertant formation of HSV1(17+) UL36 mutantsa
| HSV1 strain titrated | Titer (PFU/ml [103]) |
Ratio of mutant to revertant plaques | |
|---|---|---|---|
| Vero-HS30 | Verob | ||
| HSV1(17+)blueLox | NDc | 400,000 | ND |
| HSV1(17+)blueLox ΔUL36 | 12,000 | <1 | >12,000:1 |
| HSV1(17+)blueLox-UL36codon2211stop | 33,000 | 14 | 2,357:1 |
| HSV1(17+)blueLox-UL36codon2430stop | 29,000 | 9 | 3,222:1 |
| HSV1(17+)blueLox-UL36codon2894stop | 19,000 | <1 | >19,000:1 |
| HSV1(17+)blueLox-UL36codon2998stop | 29,000 | <1 | >29,000:1 |
a
Preparations of HSV1 UL36 mutants were titrated in triplicate on the complementing cell line Vero-HS30 and also on the noncomplementing parental Vero cells to determine the amount of revertants in parallel. For comparison, the parental HSV1(17+)blueLox strain from a parallel preparation was also titrated.
b
The input virus caused severe cytopathic effects at higher concentrations.
c
ND, not determined.